NASDAQ · SAGE
Healthcare · Biotechnology
$8.68
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 10:03 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SAGE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SAGE.
SAGE research
Company profile and research snapshot.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2025 | Scotiabank | Sector Perform | — |
| Jun 20, 2025 | Baird | Neutral | — |
| Jun 17, 2025 | Piper Sandler | Neutral | — |
| Jun 17, 2025 | Truist Securities | Hold | — |
| Jun 17, 2025 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2025
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
GlobeNewswire Inc. · Jul 5, 2025
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, including Sage Therapeutics, Coeptis Therapeutics, and AvidXchange Holdings.
GlobeNewswire Inc. · Mar 14, 2025
Grabar Law Office is investigating potential breaches of fiduciary duties by officers and directors at Mercury Systems, Methode Electronics, Monolithic Power Systems, and Sage Therapeutics. The investigations are based on allegations of financial misrepresentations and other misconduct.
GlobeNewswire Inc. · Mar 13, 2025
Grabar Law Office is investigating claims on behalf of shareholders of Fluence Energy, Kyverna Therapeutics, Mercury Systems, and Sage Therapeutics, alleging breaches of fiduciary duties by certain officers and directors.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SAGE.
No results
No recent SID articles mention SAGE.
